Preparation of trisubstituted pyridine derivatives and their application as aryl hydrocarbon receptor modulators
By developing new tri-substituted pyridine derivative compounds as AhR agonists, the problem of high activity of existing agonists but insufficient selectivity and safety is solved, and efficient activation and low toxic side effects of AhR are achieved, providing a variety of diseases. Treatment and prevention programs.
Patent Information
- Application Number
- CN202211463600.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-11-19
- Filing Date
- 2022-11-21
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2042-11-21
AI Technical Summary
When existing AhR agonists activate aromatic hydrocarbon receptors, they are highly active but lack selectivity and safety, and have toxic side effects, making it difficult to effectively treat a variety of diseases.
Develop a new tri-substituted pyridine derivative compound, prepared through synthetic routes such as Suzuki coupling reaction and condensation reaction, as a highly active and selective AhR agonist, used to activate AhR and treat psoriasis, arthritis, and Papa Kinson and other diseases.
This compound has high activity and good selectivity, low toxic side effects, can effectively activate AhR, significantly alleviate the symptoms of various diseases, and provides potential therapeutic and preventive application value.
Smart Images

Figure CN115785064B_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of medicine, and in particular to a trisubstituted pyridine derivative having an AhR activating effect, and a use and preparation method thereof. Background Art
[0002] The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor and a member of the basic helix-loop-helix transcription factor (bHLH-PAS) family. AhR is widely present in organisms, and mammals, amphibians, reptiles, and birds all contain AhR proteins. AhR is expressed in a variety of cells in the human body. It not only plays an important role in the development of blood vessels and regulation of neural function, but also has an important regulatory role in the occurrence of various diseases such as autoimmune disorders and tumors. It has become a key target for drug development.
[0003] The functional domain of AhR protein consists of three parts: bHLH domain, PAS domain and a glutamate-rich domain. The bHLH domain is located at the N-terminus of AhR protein, assisting AhR to bind to the promoter region of target genes and protein dimerization; the PAS domain assists protein dimerization by connecting with AhR nuclear translocator (ARNT) and binding with ligands to form a protein complex; the C-terminal region is a glutamate-rich domain that plays a role in recruitment and transcriptional activation. In the inactivated form, AhR usually forms a multiprotein complex with heat shock protein 90 (Hsp90), p23, X-associated protein 2 (XAP2) and AhR-associated protein 9 (ARA9) in the cytoplasm. The classical signaling pathway is that when AhR binds to the ligand and is activated, it undergoes a conformational change, exposing the nuclear localization signal sequence, and the receptor-ligand complex translocates to the nucleus, forming a heterodimer with ARNT in the nucleus. The AhR / ARNT complex binds to the heterologous biological response element (its core sequence: 5'-TNGCGTG-3') of the target gene promoter to initiate the expression of the target gene. Target genes include cytochrome P450 enzymes (CYP1A1, CYP1A2, CYP1B1), glutathione S-transferase, guanosine diphosphate glucuronosyltransferase, NAD(P)H-dependent quinone oxidoreductase-1, aldehyde dehydrogenase 3A1, and anti-breast cancer protein genes. Thus, it participates in many important physiological processes, such as the regulation of cell cycle and proliferation, immune response, circadian rhythm, tumor induction, and the expression of genes related to lipid metabolism.
[0004] AhR also exhibits different biological effects by binding to exogenous or endogenous ligands with different structural properties. Its exogenous ligands are mainly composed of polycyclic aromatic hydrocarbons (PAHs), polychlorinated biphenyls (PCBs), natural compounds and small molecules; endogenous ligands include tryptophan metabolites, heme metabolites, arachidonic acid metabolites, etc. On the one hand, AhR can be activated by ligands, leading to increased expression levels of downstream genes such as CYP1A1 and increased exogenous substance metabolizing enzymes in phase I or phase II of target gene expression products, promoting the body's metabolism of exogenous toxicants, thereby protecting the body from the effects of exogenous substances. For example, the AhR receptor agonist MCDF (6-methyl 1,3,8-trichlorodiphenylfuran) can induce the expression of the target gene CYP1A1 and enhance its metabolism, thereby inhibiting the proliferation of estrogen receptor-negative breast cancer tumor cells. On the other hand, regulating AhR and other tumor-related signaling pathways, such as AhR-ER and AhR-mitogen activated protein kinases (MAPKs), plays a role in tumorigenesis. For example, DIM (3,3'-indolylmethane) can strongly inhibit the expression of ER-α and the estrogen signaling pathway through the AhR-dependent pathway, reducing the risk of human breast cancer.
[0005] In recent years, AhR has attracted much attention in the field of immunity, especially in the process of inflammation, AhR can promote the production of Treg cells with anti-inflammatory effects. AhR agonists can induce Th0 cells to differentiate into Treg cells by activating AhR, alleviating experimental autoimmune encephalomyelitis. The administration of AhR agonist TCDD can inhibit the progression of autoimmune diseases in mouse models or improve graft survival by enhancing the proliferation of Treg cells. The AhR agonist benvimod has shown clear effects in treating psoriasis and atopic dermatitis in animals and clinical applications. In animal experiments, AhR agonists such as benvimod and laquinimod can also enhance the immune function of regulating Treg cells, and have the effect of treating arthritis, multiple sclerosis, and inflammatory bowel inflammation. The latest studies have shown that tryptophan metabolites can reduce neuroinflammation by activating the AhR pathway and have a therapeutic effect on neurodegenerative diseases such as Parkinson's disease. AhR agonist-Z425228478 can inhibit the inflammatory response of bacterial keratitis by activating AhR.
[0006] In summary, AhR agonists have potential application value in the treatment and prevention of various diseases such as psoriasis, arthritis, atopic dermatitis, Parkinson's disease, multiple sclerosis, inflammatory bowel inflammation, asthma, systemic lupus erythematosus, graft-versus-host disease, bacterial keratitis, and tumors. Summary of the invention
[0007] The purpose of the present disclosure is to provide a novel compound for synthesis and its application in AhR (aryl alkane receptor) agonist drugs. The compound, as an AhR agonist, has the advantages of high activity, good selectivity and low toxicity and side effects.
[0008] In one aspect of the present invention, there is provided a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
[0009]
[0010] in:
[0011] m is selected from 0, 1, 2 or 3; n is selected from 0, 1, 2 or 3;
[0012] Ring A is selected from 5-7 membered aryl, 5-7 membered monocyclic heteroaryl, 9-12 membered bicyclic heteroaryl, 5-7 membered heterocycloalkyl, 9-12 membered partially unsaturated bicyclic heterocyclyl;
[0013] m R2 are the same or different from each other, wherein R2 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-6 Acyl, -S(O)2R6, 5-7 membered heterocycloalkyl, the C 1-6 Acyl, 5-7 membered heterocycloalkyl, optionally substituted with one or more C 1-3 Alkyl, -NR4R5 substituted, the C 1-6 The alkyl group is optionally substituted with one or more halogen, -C(=O)NR4R5;
[0014] R1 is selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Alkenyl, C 3-6 Cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkenyl, C 3-6 Cycloalkyl is optionally substituted with one or more halogens;
[0015] L is -C(O)-,
[0016] Ring B is selected from 5-7 membered aryl, 5-7 membered monocyclic heteroaryl, 9-12 membered bicyclic heteroaryl, 9-12 membered partially unsaturated bicyclic heterocyclyl, 8-12 membered saturated spirocyclic heterocyclyl;
[0017] n R3 are the same or different from each other, wherein R3 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3Acyl, halogen, cyano, 5-7 membered heterocycloalkyl containing 1-2 atoms independently selected from N, O, S, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 The acyl group is optionally substituted with one or more halogen, cyano groups.
[0018] R4, R5, R6 are each independently selected from hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl.
[0019] In another aspect, the present disclosure relates to a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:
[0020]
[0021] in:
[0022] m is selected from 0, 1, 2 or 3; n is selected from 0, 1, 2 or 3;
[0023] Ring A is selected from 5-7 membered aryl, 5-7 membered monocyclic heteroaryl, 9-12 membered bicyclic heteroaryl, 5-7 membered heterocycloalkyl, 9-12 membered partially unsaturated bicyclic heterocyclyl;
[0024] In some specific embodiments, Ring A is selected from 5-7 membered aryl, 5-7 membered monocyclic heteroaryl containing 1-2 independently selected N, O, S atoms, 9-12 membered bicyclic heteroaryl containing 1-2 independently selected N, O, S atoms, 5-7 membered heterocycloalkyl containing 1-2 independently selected N, O, S atoms, 9-12 membered partially unsaturated bicyclic heterocyclic group containing 1-3 independently selected N, O, S atoms;
[0025] Preferably, Ring A is selected from 5-7 membered aryl, 5-7 membered monocyclic heteroaryl containing 1-2 independently selected N or O atoms, 9-12 membered bicyclic heteroaryl containing 1-2 independently selected N or O atoms, 5-7 membered heterocycloalkyl containing 1-2 N atoms, 9-12 membered partially unsaturated bicyclic heterocyclic group containing 1-3 independently selected N or O atoms;
[0026] Preferably, ring A is selected from phenyl, pyrimidinyl, pyrazolyl, benzopyrazolyl, benzimidazolyl, indazolyl, indolyl, isoxazolyl, morpholinyl, pyridinyl, triazolyl, pyrrolopyridinyl, isoindolinyl, pyridonyl, isoindolinonyl;
[0027] Preferably, ring A is selected from phenyl, pyrimidinyl, pyrazolyl, benzimidazolyl, indazolyl, indolyl, isoxazolyl, morpholinyl, pyridinyl, triazolyl, pyrrolopyridinyl, isoindolinyl, pyridonyl, isoindolinonyl;
[0028] Preferably, ring A is selected from phenyl, pyrimidinyl, pyrazolyl, benzopyrazolyl, benzimidazolyl, indazolyl, indolyl, isoxazolyl, morpholinyl, pyridinyl, triazolyl, pyrrolopyridinyl, pyridonyl, isoindolinonyl;
[0029] Preferably, ring A is not benzimidazol-2-yl
[0030] In some embodiments, Ring A is selected from
[0031] Preferably, ring A is selected from
[0032] Preferably, ring A is selected from
[0033] Preferably, ring A is selected from Preferably, Selected from
[0034] Preferably, Selected from
[0035] Preferably, Selected from
[0036] In some embodiments, m R2 are the same or different from each other, wherein R2 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-6 acyl, 5-7 membered heterocycloalkyl, the C 1-6 Acyl, 5-7 membered heterocycloalkyl, optionally substituted with one or more C 1-3 Alkyl, -NR4R5 substituted;
[0037] Preferably, R2 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-6 Acyl, 5-7 membered heterocycloalkyl containing 1-2 independently selected N and O atoms, wherein the C 1-6 Acyl, 5-7 membered heterocycloalkyl containing 1-2 independently selected N, O atoms, optionally substituted by one or more C 1-3 Alkyl, -NR4R5 substituted;
[0038] Preferably, R2 is selected from C1-3 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Acyl, 5-7 membered heterocycloalkyl containing 1-2 N atoms, the C 1-3 Acyl, 5-7 membered heterocycloalkyl containing 1-2 N atoms, optionally substituted with one or more C 1-3 Alkyl, -NR4R5 substituted;
[0039] Preferably, R2 is selected from C 1-3 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Acyl, 5-7 membered heterocycloalkyl containing 1-2 N atoms, the C 1-3 Carbonyl, 5-7 membered heterocycloalkyl containing 1-2 N atoms are optionally substituted by one or more methyl groups, -N(CH3)2;
[0040] Preferably, R2 is selected from methyl, ethyl, propyl, isopropyl, cyclopropane, methoxy, formyl, acetyl, piperazinyl, piperidinyl, morpholinyl, wherein the formyl, acetyl, piperazinyl, piperidinyl, morpholinyl are optionally substituted with one or more methyl, -N(CH3)2;
[0041] In some embodiments, R2 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-6 Acyl, -S(O)2R6, 5-7 membered heterocycloalkyl containing 1-2 independently selected N and O atoms, wherein the C 1-6 Acyl, 5-7 membered heterocycloalkyl containing 1-2 independently selected N, O atoms, optionally substituted by one or more C 1-3 Alkyl, -NR4R5 substituted, the C 1-6 The alkyl group is optionally substituted with one or more halogen, -C(=O)NR4R5; 1-6 The alkyl group is optionally substituted with one or more halogen, -C(=O)NR4R5;
[0042] Preferably, R2 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-6 Acyl, -S(O)2R6, 5-7 membered heterocycloalkyl containing 1-2 independently selected N and O atoms, wherein the C 1-6 Acyl, 5-7 membered heterocycloalkyl containing 1-2 independently selected N, O atoms, optionally substituted by one or more C 1-3Alkyl, -NR4R5 substituted; the C 1-6 The alkyl group is optionally substituted with one or more fluorine, chlorine, bromine, iodine, -C(=O)NH4R5;
[0043] Preferably, R2 is selected from C 1-3 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Acyl, -S(O)2R6, 5-7 membered heterocycloalkyl containing 1-2 N atoms, the C 1-3 Acyl, 5-7 membered heterocycloalkyl containing 1-2 N atoms, optionally substituted with one or more C 1-3 Alkyl, -NR4R5 substituted, the C 1-6 The alkyl group is optionally substituted with one or more fluorine, -C(=O)NH4R5;
[0044] Preferably, R2 is selected from C 1-3 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Acyl, -S(O)2R6, 5-7 membered heterocycloalkyl containing 1-2 N atoms, the C 1-3 Carbonyl, 5-7 membered heterocycloalkyl containing 1-2 N atoms are optionally substituted by one or more methyl groups, -N(CH3)2, wherein the C 1-6 The alkyl group is optionally substituted with one or more fluorine, -C(=O)NH2; in some embodiments, R4, R5 are each independently selected from hydrogen, C 1-6 Alkyl, more preferably hydrogen and methyl.
[0045] In some embodiments, R6 is independently selected from C 1-6 Alkyl and C 3-6 Cycloalkyl, more preferably methyl, propyl and cyclopropyl.
[0046] In some embodiments, R2 is selected from methyl, ethyl, difluoromethyl, isopropyl, cyclobutane, cyclopropane, methoxy, formyl, -CH2C(=O)NH2, -S(O)2CH3, -S(O)2(CH2)2CH3, -C(=O)CH2N(CH3)2,
[0047] In some embodiments, R2 is selected from methyl, ethyl, difluoromethyl, isopropyl, cyclobutane, cyclopropane, methoxy, formyl, -CH2C(=O)NH2, -S(O)2CH3, -S(O)2(CH2)2CH3,
[0048] Preferably, R2 is selected from methyl, isopropyl, cyclopropane, methoxy, carbonyl, -C(=O)CH2N(CH3)2,
[0049] Preferably, Selected from
[0050] In some embodiments, R1 is selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, C 1-6 Alkenyl, C 3-6 Cycloalkyl, the C 1-6 Alkyl, C 1-6 Alkenyl, C 3-6 Cycloalkyl is optionally substituted with one or more halogens;
[0051] Preferably, R1 is selected from hydrogen, deuterium, halogen, C 1-3 Alkyl, C 1-3 Alkenyl, C 3-6 Cycloalkyl, the C 1-3 Alkyl, C 1-3 Alkenyl, C 3-6 Cycloalkyl is optionally substituted with one to three halogens;
[0052] Preferably, R1 is selected from hydrogen, deuterium, fluorine, C 1-3 Alkyl, C 1-3 Alkenyl, the C 1-3 Alkyl, C 1-3 Alkenyl, C 3-6 Cycloalkyl is optionally substituted with one to three fluorines;
[0053] Preferably, R1 is selected from fluorine, methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl, isopropyl, isopropenyl, cyclopropanyl;
[0054] Preferably, R1 is selected from fluorine, methyl, isopropyl, isopropenyl, cyclopropanyl;
[0055] Preferably, R1 is methyl;
[0056] In some embodiments, L is -C(O)-,
[0057] In some embodiments, L is L is preferably
[0058] In some embodiments, Ring B is selected from 5-7 membered aryl, 5-7 membered monocyclic heteroaryl, 9-12 membered bicyclic heteroaryl, 9-12 membered partially unsaturated bicyclic heterocyclyl, 8-12 membered saturated spirocyclic heterocyclyl;
[0059] Preferably, the B ring is selected from a 5-7 membered aryl group, a 5-7 membered monocyclic heteroaryl group containing 1-2 atoms independently selected from N, O, and S, a 9-12 membered bicyclic heteroaryl group containing 1-3 atoms independently selected from N, O, and S, a 9-12 membered partially unsaturated bicyclic heterocyclic group containing 1-3 atoms independently selected from N, O, and S, and an 8-12 membered saturated spirocyclic heterocyclic group containing 1-3 atoms independently selected from N, O, and S.
[0060] Preferably, the B ring is selected from a 5-7 membered aryl group, a 5-7 membered monocyclic heteroaryl group containing 1-2 members independently selected from N or O atoms, a 9-12 membered bicyclic heteroaryl group containing 1-3 members independently selected from N or O atoms, a 9-12 membered partially unsaturated bicyclic heterocyclic group containing 1-3 members independently selected from N or O atoms, and an 8-12 membered saturated spirocyclic heterocyclic group containing 1-3 members independently selected from N or O atoms;
[0061] Preferably, the B ring is selected from phenyl, pyridyl, pyrazolyl, benzodioxolanyl, azaspirooctyl, tetrahydroisoquinolinyl;
[0062] Preferably, Ring B is selected from
[0063] In some embodiments, n R3 are the same or different from each other, wherein R3 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Acyl, halogen, cyano, 5-7 membered heterocycloalkyl containing 1-2 atoms independently selected from N, O, S, wherein the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 The acyl group is optionally substituted with one or more halogens, cyano groups;
[0064] Preferably, R3 is not selected from alkoxy and heterocycloalkyl at the same time;
[0065] Preferably, R3 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Acyl, halogen, cyano, 5-7 membered heterocycloalkyl containing 1-2 independently selected N or O atoms, the C 1-6 Alkyl, C 1-3 The acyl group is optionally substituted with one to three fluorine radicals, the C3-6 The cycloalkyl group is optionally substituted with one or more cyano groups;
[0066] Preferably, R3 is selected from methyl, trifluoromethyl, methoxy, cyclopropyl, cyclohexyl, halogen, cyano,
[0067] Preferably, R3 is selected from bromine, fluorine, chlorine, cyano, trifluoromethyl, methyl.
[0068] The present disclosure relates to the above-mentioned compounds or pharmaceutically acceptable salts thereof, including compounds represented by formula (II) or pharmaceutically acceptable salts thereof:
[0069]
[0070] Wherein, n, m, A, L, R1, R2 and R3 are as defined above.
[0071] The present disclosure relates to the above-mentioned compound or a pharmaceutically acceptable salt thereof, wherein the compound has a structure represented by the following formula (IIa), (IIb), (IIc), (IId), (IIe) or (IIf):
[0072]
[0073]
[0074] Wherein, X4, X5, X6 are selected from N, NH or CH, and n, m, R1, R2, and R3 are as defined above. The present disclosure provides the following compounds or pharmaceutically acceptable salts thereof:
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082] The present disclosure relates to a method for preparing the above-mentioned compound, which comprises the following:
[0083] Synthetic route 1:
[0084]
[0085] Step 1: Compound 1A and compound 1A-1 undergo Suzuki coupling reaction to obtain compound 1B;
[0086] Step 2: Compound 1B is extracted and purified to obtain compound 1C;
[0087] Step 3: Compound 1C is reacted with compound 1C-1 to obtain compound A1.
[0088] In some specific embodiments, in the synthetic route 1, step 1: adding compound 1A-1 to compound 1A, adding 1,4-dioxane, water, potassium carbonate, and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex to react, and obtaining compound 1B after purification;
[0089] Step 2: dissolving the compound 1B in an alcohol solvent, adding a basic solution dropwise, reacting, adjusting the pH to acidic, and obtaining 1C after extraction and purification;
[0090] Step 3: Dissolve the compound 1C in N,N-dimethylformamide, add compound 1C-1, HATU, and amine, and dropwise add DIPEA. After the reaction is completed, purify to obtain compound A1.
[0091] Synthesis route 2:
[0092]
[0093] Step 1: Compound 2A is reacted with compound 2A-1 to obtain compound 2B;
[0094] Step 2: Compound 2B is subjected to Suzuki coupling reaction with compound 2B-1 to obtain compound A2.
[0095] In some specific embodiments, in the synthetic route 2, step 1: dissolving compound 2A in N,N-dimethylformamide, adding HATU, amine, and compound 2A-1, and dropping DIPEA, after the reaction is completed, purifying to obtain compound 2B;
[0096] Step 2: Add 2B-1 to the compound 2B, and then add 1,4-dioxane, water, potassium carbonate, and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex to react, and purify to obtain compound A2.
[0097] Synthetic route 3:
[0098]
[0099] Step 1: Compound 3A undergoes condensation reaction with a compound to obtain compound 3B;
[0100] Step 2: Compound 3B is subjected to Suzuki coupling reaction with R1-B(OH)2 to obtain compound 3C;
[0101] Step 3: Compound 3C and compound 3C-1 are subjected to Suzuki coupling reaction to obtain compound A3.
[0102] In some specific embodiments, in reaction scheme 3, step 1: dissolving compound 3A in N,N-dimethylformamide, adding HATU, amine, and compound 3A-1, and dropping DIPEA, after the reaction is completed, purifying to obtain compound 3B;
[0103] Step 2: Add R1-B(OH)2, 1,4-dioxane, water, potassium carbonate, and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex to the compound 3B for reaction, and purify to obtain compound 3C;
[0104] Step 3: Add compound 3C-1 to compound 3C, add 1,4-dioxane and water, add potassium carbonate and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex under stirring at room temperature, and purify to obtain compound A3.
[0105] Synthetic route 4:
[0106]
[0107] Step 1: Compound 2A and compound 2A-1 undergo condensation reaction to obtain compound 4B;
[0108] Step 2: Compound 4B reacts with p-toluenesulfonyl chloride to obtain compound 4C;
[0109] Step 3: Compound 4C reacts with N,N-diisopropylethylamine (DIPEA) to obtain compound 4D;
[0110] Step 4: Dehydrogenation reaction of compound 4D to obtain compound 4E;
[0111] Step 5: Compound 4E and compound 4E-1 are subjected to Suzuki coupling reaction to obtain compound A4.
[0112] In some specific embodiments, in synthetic route 4, step 1: dissolving compound 2A in N,N-dimethylformamide, adding HATU and compound 2A-2, and adding DIPEA dropwise at room temperature. After the reaction is completed, purifying to obtain compound 4B;
[0113] Step 2: dissolving the compound 4B and triethylamine in tetrahydrofuran, reacting for 5 minutes, adding p-toluenesulfonyl chloride to the reaction system, extracting, drying, and removing the solvent after the reaction to obtain compound 4C, which is directly used in the next step;
[0114] Step 3: dissolving the compound 4C in tetrahydrofuran solution, adding DIPEA, reacting for 10 hours, extracting, drying, and purifying to obtain compound 4D;
[0115] Step 4: dissolving the compound 4D in anhydrous dichloromethane, adding 2,3-dichloro-5,6-dicyanobenzoquinone and 4A molecular sieves, filtering and washing after the reaction, and removing the solvent to obtain compound 4D;
[0116] Step 5: Compound 4D is reacted according to the method and steps of synthetic route 1 to obtain compound A4.
[0117] The present disclosure provides a pharmaceutical composition, which comprises the above-mentioned compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
[0118] The present disclosure provides use of the above-mentioned compound or a pharmaceutically acceptable salt thereof, and the above-mentioned pharmaceutical composition in preparing a drug for treating AhR-mediated disorders in a patient.
[0119] The present disclosure provides use of the above-mentioned compound or a pharmaceutically acceptable salt thereof, and the above-mentioned pharmaceutical composition in the preparation of an AHR agonist.
[0120] The present disclosure relates to a method of activating AhR in a patient in need thereof, comprising administering the above-mentioned compound or a pharmaceutically acceptable salt thereof, or the above-mentioned pharmaceutical composition to the patient.
[0121] The present disclosure relates to a method for treating an AhR-mediated disorder in a patient in need thereof, comprising administering the above-mentioned compound or a pharmaceutically acceptable salt thereof, or the above-mentioned pharmaceutical composition to the patient.
[0122] Preferably, the AhR-mediated disorders include, but are not limited to, psoriasis, arthritis, atopic dermatitis, Parkinson's disease, multiple sclerosis, inflammatory bowel inflammation, asthma, systemic lupus erythematosus, graft-versus-host disease, bacterial keratitis, and tumors.
[0123] The compounds disclosed herein have AhR inhibitory effects. DETAILED DESCRIPTION
[0124] According to the above contents of the present disclosure, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present disclosure, other various forms of modifications, replacements or changes may be made.
[0125] I. Definitions
[0126] Unless explicitly stated otherwise, throughout the specification and claims, the term “comprise” or variations such as “include” or “comprising”, etc., will be understood to include the stated elements or components but not to exclude other elements or components.
[0127] The compounds of the present invention may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. The compounds of the present invention containing asymmetric carbon atoms can be isolated in optically pure form or racemic form. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral raw materials or chiral reagents. Racemates, diastereomers, and enantiomers are all included within the scope of the present invention.
[0128] In this disclosure, It refers to the position where a substituent is bonded.
[0129] In this disclosure, numerical ranges refer to each integer in the given range. For example, "C 1-6 " means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms; "C 1-3 ” means that the group can have 1 carbon atom, 2 carbon atoms, or 3 carbon atoms.
[0130] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes both occurring and not occurring of said event or circumstance.
[0131] The term "substituted" or "substituted" means that any one or more hydrogen atoms on a particular atom or group are replaced by a substituent, as long as the valence state of the particular atom or group is normal and the substituted compound is stable. When the substituent is a keto group (i.e., =O), it means that two hydrogen atoms are replaced. Unless otherwise specified, the type and number of substituents can be any on the basis of chemically achievable.
[0132] When any variable (such as R n ) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with one to three R, the group may be optionally substituted with up to three R, and each occurrence of R is an independent choice. In addition, combinations of substituents and / or variants thereof are permitted only if such combinations result in stable compounds.
[0133] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, including straight-chain or branched saturated hydrocarbon groups, having the indicated number of carbon atoms. 1-6 "Alkyl" includes C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl, examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, n-hexyl, 2-hexyl, 3-hexyl, etc. It may be divalent, such as methylene, ethylene.
[0134] The term "alkoxy" may be linear, branched or cyclic. The number of carbon atoms of the alkoxy group is not particularly limited, but is preferably 1 to 20. Specific examples thereof include methoxy, ethoxy, n-propoxy, isopropoxy, i-propyloxy, n-butoxy, isobutoxy, tert-butoxy, sec-butoxy, n-pentoxy, neopentoxy, isopentyloxy, n-hexyloxy, 3,3-dimethylbutoxy, 2-ethylbutoxy, n-octyloxy, n-nonyloxy, n-decyloxy, etc., but are not limited thereto.
[0135] The term "carbonyl" or "carboxyl" includes structures in which a carbon of a compound or fragment is connected to an oxygen atom via a double bond. Examples of carbonyl-containing moieties include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, and the like.
[0136] The term "acyl" is a carbonyl structure in which the carbon atom of the carbonyl group is connected to hydrogen (i.e., formyl), an aliphatic group (C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, such as acetyl), a cycloalkyl group (C3-C8 cycloalkyl), a heterocyclic group (C3-C8 heterocycloalkyl and C5-C6 heteroaryl), an aryl group (C6 aryl, such as benzoyl). The acyl group may be unsubstituted or substituted acyl (e.g., salicyl).
[0137] In the present disclosure, examples of the halogen group may include fluorine, chlorine, bromine, or iodine.
[0138] In this disclosure, the term "cycloalkyl" refers to a monocyclic saturated hydrocarbon system without heteroatoms and double bonds. For example, the term "C 3-6 Examples of "cycloalkyl" include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
[0139] In the present disclosure, the term "aryl" refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated π electron system, which is obtained by removing a hydrogen atom from a single carbon atom of a parent aromatic ring system. It includes a saturated, partially unsaturated ring, or a bicyclic group of an aromatic ring fused with an aromatic carbocyclic ring. Specific examples thereof include phenyl or naphthyl, but are not limited thereto.
[0140] In the present disclosure, the term "heterocycloalkyl" refers to a 5-12 membered saturated non-aromatic system having ring carbon atoms and 1 to 2 ring heteroatoms. Specific examples of the heterocyclic group include piperidinyl or tetrahydropyrrolyl, but are not limited thereto.
[0141] In the present disclosure, the term "heteroaryl" refers to a monovalent aromatic group containing at least one heteroatom independently selected from nitrogen, oxygen and sulfur. The heteroaryl group may be a monocyclic ring or a polycyclic ring system, such as a bicyclic ring, wherein two or more rings exist in the form of a cyclic ring, a bridged ring or a spirocyclic ring, wherein at least one ring contains one or more heteroatoms. Specific examples of heteroaryl groups include pyridyl, thienyl, imidazolyl, pyrimidinyl, pyridyl, furanyl, pyrazinyl, thiazolyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl, imidazopyridyl, benzofuranyl, pyridazinyl, isoindolyl, pyridonyl, but are not limited thereto.
[0142] The term "heterocycle" refers to a 5-12 membered saturated non-aromatic system having ring carbon atoms and 1 to 2 ring heteroatoms, wherein the heteroatoms are independently selected from nitrogen, sulfur or oxygen atoms. In heterocyclic groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as long as the valence permits. The heterocycle may be a monocyclic or polycyclic system, such as a bicyclic ring, wherein two or more rings exist in the form of a cyclic, bridged or spirocyclic ring, wherein at least one ring contains one or more heteroatoms. In a spirocyclic heterocyclic group, two different rings have one atom in common, and an example of a spirocyclic heterocyclic group is an azaspiropentyl group, but is not limited thereto.
[0143] The term "partially unsaturated bicyclic heterocycle" means a bicyclic group containing C atoms and at least one of heteroatoms such as N, O, S as ring members, the bicyclic group is partially unsaturated, and contains at least one C-C double bond. The largest unsaturated heterocycle contains the maximum number of C-C double bonds allowed by the ring size and double bonds between C atoms and heteroatoms. The partially unsaturated bicyclic heterocycle contains less double bonds than the number allowed by the ring size. Specific examples of partially unsaturated bicyclic heterocycles include, but are not limited to, benzofuranyl, benzothiophenyl, quinoxalinyl, quinazolinyl, isoindolinone, pteridinyl, and the like.
[0144] abbreviation:
[0145] Ts: p-toluenesulfonyl;
[0146] DIPEA: N,N-diisopropylethylamine;
[0147] Drug or drug composition
[0148] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit / risk ratio.
[0149] The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness of the free acids and bases of a particular compound without adverse biological effects, such as acid (including organic acids and inorganic acids) addition salts or base addition salts (including organic bases and inorganic bases).
[0150] Pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. Generally, the preparation method of such salts is: in water or an organic solvent or a mixture of the two, these compounds in free acid or base form are reacted with a stoichiometric amount of an appropriate base or acid to prepare.
[0151] The medicaments or pharmaceutical compositions of the present disclosure may be administered orally, topically, parenterally or mucosally (eg, buccally, by inhalation or rectally) in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers.
[0152] For oral administration in the form of tablets or capsules, the active drug component can be mixed with non-toxic, pharmaceutically acceptable excipients such as binders (e.g., pregelatinized corn starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, sucrose, glucose, mannitol, sorbitol and other reducing and non-reducing sugars, microcrystalline cellulose, calcium sulfate or dibasic calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica, stearic acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate, etc.); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate), coloring and flavoring agents, gelatin, sweeteners, natural and synthetic gums (such as acacia, tragacanth or alginates), buffer salts, carboxymethylcellulose, polyethylene glycol, waxes, and the like. For oral administration in liquid form, the drug component can be combined with a non-toxic, pharmaceutically acceptable inert carrier (e.g., ethanol, glycerol, water), an anti-settling agent (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats), an emulsifier (e.g., lecithin or gum arabic), a non-aqueous carrier (e.g., almond oil, oily esters, ethanol or fractionated vegetable oils), a preservative (e.g., methyl or propyl p-hydroxybenzoate or sorbic acid), etc. Stabilizers such as antioxidants (BHA, BHT, propyl citric acid, sodium ascorbate, citric acid) can also be added to stabilize the dosage form.
[0153] Tablets containing the active compound can be coated by methods well known in the art. The compositions of the present disclosure containing the compound of formula I as the active compound can also introduce beads, microspheres or microcapsules, such as those constructed from polyglycolic acid / lactic acid (PGLA). Liquid preparations for oral administration can take the form of, for example, solutions, syrups, emulsions or suspensions or they can be presented as dry products reconstituted with water or other suitable excipients before use. Preparations for oral administration can be suitably formulated to release the active compound in a controlled or delayed manner.
[0154] The medicine or pharmaceutical composition of the present disclosure can be delivered parenterally, that is, administered intravenously (iv), intracerebroventricularly (icv), subcutaneously (sc), intraperitoneally (ip), intramuscularly (im), subcutaneously (sd) or intradermally (id), by direct injection, for example, by bolus injection or continuous infusion. The formulation for injection can be presented in unit dosage form, for example, in an ampoule or multi-dose container with an added preservative. The composition can be in the shape of an excipient, in the form of a suspension, solution or emulsion in an oil or aqueous vehicle, and can include formulation agents such as anti-settling agents, stabilizers and / or dispersants. Alternatively, the active ingredient can be reconstituted with a suitable carrier (e.g., sterile pyrogen-free water) before use in powder form.
[0155] The medicaments or pharmaceutical compositions of the present disclosure may also be formulated for rectal administration, for example, as suppositories or retention enemas (eg, containing conventional suppository bases such as cocoa butter or other glycerides).
[0156] The term "treatment" includes suppressing, alleviating, preventing or eliminating one or more symptoms or side effects associated with the treated disease, illness or disorder. The term "effective amount" or "therapeutically effective amount" refers to a dosage that is enough to treat, suppress or alleviate one or more symptoms of the treated disease state or otherwise provide the desired pharmacological and / or physiological effects. The precise dosage will vary according to a variety of factors, such as the variable (e.g., age, immune system health, etc.) that the subject depends on, the disease or illness, and the treatment applied. The effect of the effective amount can be relative to a control. These controls are known in the art and discussed in this article, and can be, for example, the condition of the subject before or when the drug or drug combination is not applied, or in the case of a drug combination, the combined effect can be compared with the effect of only applying a drug.
[0157] The term "pharmaceutical composition" means a composition comprising the compound described in the present disclosure or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable ingredient selected from the following depending on the mode of administration and the nature of the dosage form, including but not limited to: carriers, diluents, adjuvants, excipients, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, fragrances, antibacterial agents, antifungal agents, lubricants, dispersants, temperature-sensitive materials, temperature regulators, adhesives, stabilizers, suspending agents, etc.
[0158] II. Embodiment
[0159] The present disclosure is further explained below with reference to examples. The description of specific exemplary embodiments of the present disclosure is for the purpose of illustration and demonstration. These descriptions are not intended to limit the present disclosure to the precise form disclosed, and it is clear that many changes and variations can be made according to the teachings of the present disclosure specification. The purpose of selecting and describing exemplary embodiments is to explain the specific principles of the present disclosure and its practical application, so that those skilled in the art can realize and utilize various different exemplary embodiments of the present disclosure and various different selections and changes.
[0160] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0161] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0162] The compound represented by the chemical formula (I) can be prepared as follows: Synthesis Scheme 1, 2, 3 or 4. The substituents can be bonded by methods known in the art, and the type, position or number of the substituents can be changed according to techniques known in the art. Substituents can be bonded as in Synthesis Scheme 1, 2, 3 or 4, but are not limited thereto.
[0163] The compounds disclosed herein are prepared using the following synthetic routes:
[0164] Synthetic route 1:
[0165]
[0166] Step 1: Add 6-chloro-3-R1-pyridine carboxylic acid methyl ester, 1A-1,1,4-dioxane and water to a single-mouth bottle, add potassium carbonate, add [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex, replace with argon three times, heat to 95 degrees Celsius for 4 hours, cool naturally to room temperature, evaporate the solvent under reduced pressure, and purify with silica gel to obtain compound 1B;
[0167] Step 2: Add 1B to a single-mouth bottle, dissolve it with methanol, add 2N NaOH aqueous solution dropwise, react at room temperature for 4 hours, adjust the pH to 3-4 with 2N hydrochloric acid, extract with ethyl acetate and water, combine the organic phases, and spin-dry the solvent to obtain compound 1C;
[0168] Step 3: Dissolve 1C in N,N-dimethylformamide, add HATU, amine, and dropwise add DIPEA, and react at room temperature. After the reaction is completed, remove the solvent and purify with silica gel to obtain compound A1.
[0169] Synthetic route 2:
[0170]
[0171] Step 1: Dissolve 6-chloro-3-R1-pyridine carboxylic acid in N,N-dimethylformamide, add HATU, amine, and dropwise add DIPEA, and react at room temperature for one hour. After the reaction is completed, remove the solvent and purify with silica gel to obtain compound 2B;
[0172] Step 2: Add 2B, 2B-1,1,4-dioxane and water to a single-mouth bottle, add potassium carbonate, [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex, replace with argon three times, heat to 95 degrees Celsius and react for 4 hours, cool naturally to room temperature, evaporate the solvent under reduced pressure, purify with silica gel to obtain compound A2.
[0173] Synthetic route 3:
[0174]
[0175] Step 1: Dissolve 3-bromo-6-chloro-2-pyridinecarboxylic acid in N,N-dimethylformamide, add HATU, amine, and dropwise add DIPEA, and react at room temperature. After the reaction is completed, remove the solvent and purify with silica gel to obtain compound 3B;
[0176] Step 2: Add 3B, R1-B(OH)2, 1,4-dioxane and water, potassium carbonate, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex into a single-mouth bottle, replace with argon three times, heat to 95 degrees Celsius for 4 hours, cool naturally to room temperature, evaporate the solvent under reduced pressure, and purify with silica gel to obtain compound 3C;
[0177] Step 3: Add 3C, boric acid, 1,4-dioxane and water to a single-mouth bottle, add potassium carbonate and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex under stirring at room temperature, replace with argon three times, heat to 100 degrees Celsius and react for 6 hours, cool naturally to room temperature, and purify with silica gel to obtain compound A3.
[0178] Synthetic route 4:
[0179]
[0180] Step 1: Dissolve 6-chloro-3-R1-pyridine carboxylic acid in N,N-dimethylformamide, add HATU, DL-phenylglycinol, and dropwise add DIPEA at room temperature. After the addition is complete, react at room temperature for 2 hours. After the reaction is complete, remove the solvent and purify with silica gel to obtain compound 4B;
[0181] Step 2: Dissolve 4B and triethylamine in tetrahydrofuran, stir at 0 degrees Celsius for 5 minutes, then slowly drop p-toluenesulfonyl chloride into the reaction system, warm to room temperature and react for 6 hours after the dropwise addition. Remove the solvent by vortexing, extract with ethyl acetate and water three times, combine the organic phases, dry with anhydrous sodium sulfate, and remove the solvent by vortexing to obtain a crude product (4C) which is directly used in the next step;
[0182] Step 3: Dissolve 4C in tetrahydrofuran solution, add DIPEA, heat to 75 degrees Celsius, and keep warm for 10 hours. Remove the solvent from the reaction solution, add ethyl acetate and water to extract three times, combine the organic phases, dry over anhydrous sodium sulfate, spin dry the solvent, and purify with silica gel to obtain 4D;
[0183] Step 4: Dissolve 4D in anhydrous dichloromethane, add 2,3-dichloro-5,6-dicyanobenzoquinone and 4A molecular sieves, and react at room temperature for 4 hours. After the reaction is completed, filter, wash the filter cake with anhydrous dichloromethane twice, and spin-dry the solvent to obtain 4E;
[0184] Step 5: 4E is processed according to the method of synthetic route 1 to obtain the final product.
[0185] Example 1: Preparation of Compound 1
[0186] Compound 1 was prepared by the method of synthetic route 1, and the specific reaction was as follows:
[0187]
[0188] Step 1: Add 6-chloro-3-methylpicolinic acid methyl ester (185.6 mg, 1 mmol) to a single-mouth bottle, add 5-pyrimidineboronic acid (185.9 mg, 1.5 mmol), 1,4-dioxane (10 mL) and water (2 mL), add potassium carbonate (414 mg, 3 mmol) under stirring at room temperature, add [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (40.8 mg, 0.05 mmol) , argon gas was replaced 3 times, the temperature was raised to 95 degrees Celsius for 4 hours, and the mixture was cooled naturally to room temperature. The solvent was evaporated under reduced pressure, ethyl acetate and water were added to the residue for extraction, and the organic phase was washed with water until neutral, anhydrous sodium sulfate was added for drying, and the mixture was filtered. The filtrate was evaporated under reduced pressure to remove the solvent and purified on silica gel (ethyl acetate / petroleum ether=1 / 5) to obtain 184.1 mg of compound 1A (methyl 3-methyl-6-(pyrimidin-5-yl)picolinate), with a yield of 80% and Ms+1:230.1;
[0189] Step 2: Add 3-methyl-6-(pyrimidin-5-yl)picolinic acid methyl ester (92 mg, 0.5 mmol) to a single-mouth bottle, add methanol (5 mL) to dissolve, add 2N NaOH aqueous solution (1 mL) dropwise at 0°C, react at room temperature for 4 hours after the addition is complete, TLC plate, the raw material reacts completely, adjust the pH to 3-4 with 2N hydrochloric acid, extract with ethyl acetate and water three times, combine the organic phases, spin-dry the solvent to obtain 80 mg of crude compound 1B (3-methyl-6-(pyrimidin-5-yl)picolinic acid), which is directly used in the next step. Ms+1: 216.1;
[0190] Step 3: The crude product obtained in the previous step was dissolved in N, N-dimethylformamide in a 50 mL single-mouth bottle, HATU (212.8 mg, 0.56 mmol), 4-bromoaniline (78 mg, 0.45 mmol), and DIPEA (144 mg, 1.12 mmol) was added dropwise at room temperature. After the addition was completed, the reaction was carried out at room temperature for one hour. After the reaction was completed, the solvent was removed by rotation, and the mixture was purified by silica gel (ethyl acetate / petroleum ether=1 / 3) to obtain 45 mg of compound 1 (N-(4-bromophenyl)-3-methyl-6-(pyrimidin-5-yl)pyridineamide), with a yield of 32.7% and Ms+1:370.2.
[0191] Table 1 Compounds synthesized according to the method of Example 1 and data characterization
[0192]
[0193]
[0194]
[0195]
[0196] Example 2: Preparation of Compound 14
[0197] Compound 14 was prepared in the manner of synthetic route 2. The specific reaction is as follows:
[0198]
[0199] Step 1: Dissolve 6-chloro-3-methylpicolinic acid with (79.8 mg, 0.47 mmol) N, N-dimethylformamide in a 50 mL single-mouth bottle, add HATU (212.8 mg, 0.56 mmol), m-methylaniline (48 mg, 0.45 mmol), and dropwise add DIPEA (144 mg, 1.12 mmol) at room temperature. After the addition is complete, react at room temperature for one hour. After the reaction is complete, remove the solvent and purify with silica gel (ethyl acetate / petroleum ether = 1 / 3) to obtain 56.5 mg of compound 14A (6-chloro-3-methyl-N-(m-tolyl)picolinamide), yield: 46.6%, Ms+1: 260.1;
[0200] Step 2: Add 6-chloro-3-methyl-N-(m-tolyl)picolinamide (56.5 mg, 0.22 mmol) to a single-mouth bottle, add indazole-6-boric acid (53 mg, 0.33 mmol), 1,4-dioxane (5 mL) and water (1 mL), add potassium carbonate (91 mg, 0.66 mmol) under stirring at room temperature, add [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (8 mg, 0.01 mmol), argon The mixture was replaced with gas for 3 times, heated to 95 degrees Celsius for 4 hours, cooled naturally to room temperature, and the solvent was evaporated under reduced pressure. Ethyl acetate and water were added to the residue for extraction, and the organic phase was washed with water until neutral, dried over anhydrous sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure to remove the solvent and purified on silica gel (ethyl acetate / petroleum ether=1 / 3) to obtain 52 mg of compound 14 (6-(1H-indazol-6-yl)-3-methyl-N-(m-tolyl)picolinamide), with a yield of 69.5% and Ms+1:343.2.
[0201] Table 2 Compounds synthesized according to the method of Example 14 and data characterization
[0202]
[0203]
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210]
[0211] Example 3: Preparation of Compound 38
[0212] Compound 38 was prepared in the manner of synthetic route 3. The specific reaction is as follows:
[0213]
[0214] Step 1: Dissolve 3-bromo-6-chloro-2-pyridinecarboxylic acid with (237 mg, 1 mmol) N, N-dimethylformamide in a 50 mL single-mouth bottle, add HATU (456 mg, 1.2 mmol), p-trifluoromethylaniline (177.2 mg, 1.1 mmol), and dropwise add DIPEA (387 mg, 3 mmol) at room temperature. After the addition is complete, react at room temperature for one hour. After the reaction is complete, remove the solvent and purify with silica gel (ethyl acetate / petroleum ether=1 / 3) to obtain 265 mg of compound 38A (3-bromo-6-chloro-N-(4-(trifluoromethyl)phenyl)pyridineamide), yield: 69.8%, Ms+1: 379.1;
[0215] Step 2: Add 3-bromo-6-chloro-N-(4-(trifluoromethyl)phenyl)picolinamide (75.8 mg, 0.2 mmol) to a single-mouth bottle, add cyclopropylboric acid (25.8 mg, 0.3 mmol), 1,4-dioxane (5 mL) and water (1 mL), add potassium carbonate (82.8 mg, 0.6 mmol) under stirring at room temperature, add [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (16 mg, 0.02 mmol) l), argon replacement 3 times, heating to 95 degrees Celsius for 4 hours, naturally cooling to room temperature, distilling off the solvent under reduced pressure, adding ethyl acetate and water to the residue for extraction, separating the liquids, washing the organic phase with water until neutral, adding anhydrous sodium sulfate to dry, filtering, distilling off the solvent from the filtrate under reduced pressure, and purifying with silica gel (ethyl acetate / petroleum ether=1 / 3) to obtain 37 mg of compound 38B (5-chloro-3-cyclopropyl-N-(4-(trifluoromethyl)phenyl)picolinamide), yield: 54.2%, Ms+1: 341.1;
[0216] Step 3: Add 5-chloro-3-cyclopropyl-N-(4-(trifluoromethyl)phenyl)picolinamide (18 mg, 0.053 mmol) to a single-mouth bottle, add 1-methyl-1H-pyrazole-4-boric acid (10 mg, 0.08 mmol), 1,4-dioxane (5 mL) and water (1 mL), add potassium carbonate (18 mg, 0.13 mmol) under stirring at room temperature, add [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (3 mg, 0.004 mmol) , argon gas was replaced 3 times, the temperature was raised to 100 degrees Celsius for reaction for 6 hours, naturally cooled to room temperature, the solvent was evaporated under reduced pressure, ethyl acetate and water were added to the residue for extraction, the liquids were separated, the organic phase was washed with water until neutral, anhydrous sodium sulfate was added for drying, and the filtrate was filtered. The solvent was evaporated under reduced pressure and then purified on silica gel (ethyl acetate / petroleum ether=1 / 4) to obtain 6 mg of compound 38 (3-cyclopropyl-6-(1-methyl-1H-pyrazol-4-yl)-N-(4(trifluoromethyl)phenyl)picolinamide), yield: 29.3%, Ms+1: 387.1.
[0217] Table 3 Compounds synthesized according to the method of Example 38 and data characterization
[0218]
[0219] Example 4: Synthesis of Compound 42
[0220] The specific reactions are as follows:
[0221]
[0222] Step 1: Dissolve 6-chloro-3-methylpicolinic acid with (171.6 mg, 1 mmol) N, N-dimethylformamide in a 50 mL single-mouth bottle, add HATU (456 mg, 1.2 mmol), DL-phenylglycinol (165.4 mg, 1.2 mmol), and dropwise add DIPEA (322.5 mg, 2.5 mmol) at room temperature. After the addition is complete, react at room temperature for 2 hours. After the reaction is complete, remove the solvent and purify with silica gel (ethyl acetate / petroleum ether=1 / 4) to obtain 220 mg of compound 42A (6-chloro-N-(2-hydroxy-1-phenylethyl)-3-methylpicolinamide), yield: 75.8%, Ms+1: 291.1;
[0223] Step 2: Dissolve 6-chloro-N-(2-hydroxy-1-phenylethyl)-3-methylpicolinamide (220 mg, 0.76 mmol) and triethylamine (191.9 mg, 1.9 mmol) in tetrahydrofuran, put into a 50 mL single-mouth bottle, stir at 0 degrees Celsius for 5 minutes, then slowly add p-toluenesulfonyl chloride (289.8 mg, 1.52 mmol) dropwise to the reaction system, and after the addition is complete, warm to room temperature and react for 6 hours. LC-Ms detection showed that the raw material reacted completely. Remove the solvent by spinning, extract three times with ethyl acetate and water, combine the organic phases, dry with anhydrous sodium sulfate, spin remove the solvent, and obtain a pale yellow crude product (compound 42B) which is directly used in the next step;
[0224] Step 3: Dissolve the crude product obtained in the previous step in 20 mL of tetrahydrofuran solution in a 50 mL single-mouth bottle, add DIPEA (588.24 mg, 4.56 mmol), heat to 75 degrees Celsius, and keep warm for 10 hours. Monitor the complete reaction of the raw materials using LC-Ms. The reaction solution was vortexed to remove the solvent, ethyl acetate and water were added and extracted three times, the organic phases were combined, dried over anhydrous sodium sulfate, the solvent was dried, and purified on silica gel (ethyl acetate / petroleum ether = 1 / 3) to obtain an off-white solid (Compound 42C, 3-(6-chloro-3-methylpyridin-2-yl)-4-phenyl-4,5-dihydrooxazole) 180 mg, yield: 87%, Ms+1: 273.1;
[0225] Step 4: Dissolve 3-(6-chloro-3-methylpyridin-2-yl)-4-phenyl-4,5-dihydrooxazole (180 mg, 0.66 mmol) in anhydrous dichloromethane, add 2,3-dichloro-5,6-dicyanobenzoquinone (300 mg, 1.32 mmol) and 4A molecular sieves (100 mg), and react at room temperature for 4 hours. Use LC-Ms to monitor the complete reaction of the raw materials. After the reaction is completed, filter and wash the filter cake with anhydrous dichloromethane twice, and spin off the solvent to obtain 112 mg of light yellow oily compound 42D (2-(6-chloro-3-methylpyridin-2-yl)-4-benzoxazole), yield: 99%, Ms+1: 271.1;
[0226] Step 5: 56 mg of 2-(6-chloro-3-methylpyridin-2-yl)-4-benzoxazole was treated according to the method of Example 1 to obtain 30 mg of 2-(3-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-4-benzoxazole, with a yield of 45.8% and Ms+1: 317.1.
[0227] Table 4 Compounds synthesized according to the method of Example 42 and data characterization
[0228]
[0229]
[0230] Example 5: Preparation of Compound 92
[0231] Compound 92 was prepared by the method of synthetic route 2. The specific reaction is as follows:
[0232]
[0233] Step 1: Dissolve 6-chloro-3-methylpicolinic acid (798 mg, 4.7 mmol) in N, N-dimethylformamide in a 50 mL single-mouth bottle, add HATU (2128 mg, 5.6 mmol), m-trifluoromethylaniline (720 mg, 4.5 mmol), and dropwise add DIPEA (1440 mg, 11.2 mmol) at room temperature. After the addition is complete, react at room temperature for one hour. After the reaction is complete, remove the solvent and purify with silica gel (ethyl acetate / petroleum ether=1 / 3) to obtain 960 mg of compound 92A (6-chloro-3-methyl-N-(m-trifluoromethylphenyl)picolinamide), yield: 65%, Ms+1: 315.1;
[0234] Step 2: Add 6-chloro-3-trifluoromethyl-N-(trifluoromethylphenyl)picolinamide (31.5 mg, 0.1 mmol) to a single-mouth bottle, add 4-pyrazoleboronic acid pinacol ester (19.4 mg, 0.1 mmol), 1,4-dioxane (5 mL) and water (1 mL), add potassium carbonate (27.6 mg, 0.2 mmol) under stirring at room temperature, add [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (8 mg, 0.01 mmol), argon was replaced 3 times, the temperature was raised to 95 degrees Celsius for 4 hours, and the mixture was naturally cooled to room temperature. The solvent was evaporated under reduced pressure, ethyl acetate and water were added to the residue for extraction, the liquids were separated, the organic phase was washed with water until neutral, anhydrous sodium sulfate was added for drying, and the filtrate was filtered. The solvent was evaporated from the filtrate under reduced pressure and then purified on silica gel (ethyl acetate / petroleum ether=1 / 3) to obtain 32 mg of compound 92B (3-methyl-6-pyrazol-4-yl-N-trifluoromethylpicolinamide), yield: 92.2%, Ms+1: 347.2.
[0235] Step 3: Add 3-methyl-6-pyrazol-4-yl-N-trifluoromethylpicolinamide (32 mg, 0.09 mmol) to a single-mouth bottle, add dichloromethane (5 mL), add triethylamine (19 mg, 0.19 mmol) under stirring at room temperature, cool the system to 0 degrees Celsius, add methylsulfonyl chloride (11 mg, 0.1 mmol) dropwise, warm to 25 degrees Celsius and react for 2 hours, evaporate the solvent under reduced pressure, add ethyl acetate and water to the residue for extraction, separate the liquids, wash the organic phase with water until neutral, add anhydrous sodium sulfate to dry, filter, evaporate the filtrate under reduced pressure to remove the solvent and purify it on silica gel (ethyl acetate / petroleum ether = 1 / 3) to obtain compound 92 (3-methyl-6-methylsulfonyl-4-pyrazole-N-trifluoromethylbenzenepicolinamide) 32 mg, yield: 83.7%, Ms+1: 425.1.
[0236] Table 5 Compounds synthesized according to the method of Example 92 and data characterization
[0237]
[0238]
[0239] Example 6: Preparation of Compound 46
[0240]
[0241] 6-Chloro-3-methyl-N-(4-(trifluoromethyl)phenyl)picolinamide (31.4 mg, 0.1 mmol) was dissolved in anhydrous N-methylpyrrolidone (5 mL), potassium carbonate (41.4 mg, 0.3 mmol) was added, the temperature was raised to 165 degrees Celsius for 6 hours, and the mixture was naturally cooled to room temperature. It was purified by silica gel (ethyl acetate / petroleum ether=1 / 3) to give 3-methyl-6-morpholine-N-(4-(trifluoromethyl)phenyl)picolinamide 20 mg, yield: 54.8%, Ms+1: 366.1. 1 H NMR(400MHz, CDCl3)δ9.13(s,1H),7.84-7.78(m,2H),7.72-7.66(m,2H),7.42(m,1H) ,7.13(d,J=8.6Hz,1H),3.86-3.82(m,4H),3.79-3.75(m,4H),2.62(d,J=1.0Hz,3H).
[0242] Example 7: Experimental study on the effect of the disclosed compounds on stimulating AhR targets in vitro
[0243] The in vitro activity of the above compounds was demonstrated in the following assays:
[0244] Using HepG2-Lucia TMAhR cells are used to screen small molecule compounds that stimulate aryl hydrocarbon receptor (AhR). TM AhR cells were engineered from the human HepG2 hepatoma cell line and were used to study AhR genomic signaling induction by monitoring the activity of a luciferase reporter protein.
[0245] (1) Experimental Materials
[0246] DMEM culture medium was purchased from Gibco, penicillin and streptomycin were purchased from Hyclone, Tapinarof was purchased from MedChemExpress (MCE), and Dual Luciferase Reporter Assay Kit was purchased from Novozyme Biotechnology Co., Ltd.
[0247] (2) Experimental methods
[0248] HepG2-Lucia TM AhR cells were cultured in DMEM + 10% FBS + 1% penicillin / streptomycin medium at 37°C and 5% CO2 in an incubator. TM AhR cells were collected at 8 × 10 3cells / well were inoculated in a 96-well plate and cultured overnight in a cell culture incubator at 37°C and 5% CO2. The next day, the test compound was diluted with culture medium to the corresponding concentration (0.001-10μM) and added to the corresponding wells of the 96-well plate. Three replicates were performed for each sample concentration. Three solvent control wells and three positive drug (Tapinarof 10μM) control wells were set up on each plate. The positive drug Tapinarof was also diluted and added to the test for each test. After adding the drug, the 96-well plate was placed in a cell culture incubator at 37°C and 5% CO2 for 24h. 10min before the end of the culture, 5×CellLysis Buffer and ddH2O in the Dual Luciferase Reporter Assay Kit were mixed in a ratio of 1:4 to prepare 1×Cell Lysis Buffer for standby use. After the culture was completed, the culture medium was removed, 20μL 1×Cell Lysis Buffer was added to each well, and the well was placed on a horizontal shaker for 15min to fully lyse the cells. During this period, mix the appropriate amount of reaction stop buffer (Stop & Reaction Buffer) and luciferase substrate (Renilla Substrate) in a ratio of 50:1 for use (protected from light), and prepare a light-proof 96-well white plate. After the cell lysis is completed, transfer the cell lysate (13 μL) to the corresponding wells of the 96-well white plate, and use a microplate luminescence detector to measure the results. And calculate the DRE luciferase activity fold (DRE Luciferase activity (fold)) according to the following formula:
[0249] DRE luciferase activity multiple = average value of sample duplicate wells / average value of solvent control duplicate wells
[0250] The luciferase activity multiple of the sample and the positive drug Tapinarof (10 μM) can be used to evaluate the agonist effect of the sample on AhR. Finally, Graphpad Prism 5.0 software was used to fit the curve and calculate the EC value of the compound to be tested for agonist AhR target. 50 Values are shown in the following table, where "AAAAA" indicates EC 50 <20nM; “AAAA” indicates EC 50 Greater than or equal to 20nM and less than 200nM; "AAA" means EC 50 Greater than or equal to 200nM and less than or equal to 500nM; "AA" means EC 50 Greater than or equal to 500nM and less than or equal to 1000nM; "A" means EC 50>1000 nM; for the agonist fold value, "BBB" means higher than 10 times; "BB" means the fold is greater than or equal to 5 and less than or equal to 10; "B" means the fold is less than 5.
[0251] Table 6 EC values of the compounds in the examples determined in vitro 50 Value and excitement effect
[0252]
[0253]
Claims
1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof, in: m is selected from 0, 1, 2 or 3; n is selected from 0, 1, 2 or 3; Ring A is selected from pyrimidinyl, pyrazolyl, benzimidazolyl, indazolyl, indolyl, isoxazolyl, morpholinyl, pyridinyl, triazolyl, pyrrolopyridinyl; m R2 are the same or different from each other, wherein R2 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-6 Acyl, -S(O)2R6, 5-7 membered heterocycloalkyl, the C 1-6 Acyl, 5-7 membered heterocycloalkyl, optionally substituted with one or more C 1-3 Alkyl, -NR4R5 substituted, the C 1-6 The alkyl group is optionally substituted with one or more halogen, -C(=O)NR4R5; n R3 are the same or different from each other, wherein R3 is selected from methyl, trifluoromethyl, cyclopropyl, halogen, cyano, ; R1 is selected from fluorine, methyl, isopropenyl or cyclopropane; L is or ; Ring B is selected from or ; R4, R5, R6 are each independently selected from hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl.
2. The compound according to claim 1, wherein Ring A is selected from , , , , , , , , , , , , , , , .
3. The compound according to claim 1, wherein Selected from , , , , , , , , , , , , , , , , .
4. The compound according to claim 1, wherein Selected from , , , .
5. The compound according to any one of claims 1 to 4, wherein R2 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-6 Acyl, -S(O)2R6, 5-7 membered heterocycloalkyl containing 1-2 independently selected N and O atoms, wherein the C 1-6 Acyl, 5-7 membered heterocycloalkyl containing 1-2 independently selected N, O atoms, optionally substituted by one or more C 1-3 Alkyl, -NR4R5 substituted, the C 1-6 The alkyl group is optionally substituted with one or more halogen, -C(=O)NR4R5.
6. The compound according to claim 5, wherein R2 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-6 acyl, 5-7 membered heterocycloalkyl, said C 1-6 Acyl, 5-7 membered heterocycloalkyl, optionally substituted with one or more C 1-3 Alkyl, -NR4R5 substituted.
7. The compound according to claim 5, wherein R2 is selected from C 1-3 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Acyl, 5-7 membered heterocycloalkyl containing 1-2 N atoms, the C 1-3 Acyl, 5-7 membered heterocycloalkyl containing 1-2 N atoms, optionally substituted with one or more C 1-3 Alkyl, -NR4R5 substituted.
8. The compound according to claim 5, wherein R2 is selected from C 1-3 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Acyl, 5-7 membered heterocycloalkyl containing 1-2 N atoms, the C 1-3 The carbonyl group and the 5-7 membered heterocycloalkyl group containing 1-2 N atoms are optionally substituted by one or more methyl groups, -N(CH3)2.
9. The compound according to claim 5, wherein R2 is selected from methyl, ethyl, propyl, isopropyl, cyclopropanyl, methoxy, formyl, acetyl, piperazinyl, piperidinyl, morpholinyl, and the formyl, acetyl, piperazinyl, piperidinyl, morpholinyl are optionally substituted with one or more methyl, -N(CH3)2.
10. The compound according to any one of claims 1 to 4 and 6 to 9, wherein R4 and R5 are each independently selected from hydrogen, C 1-6 alkyl.
11. The compound according to claim 10, wherein R4 and R5 are each independently selected from hydrogen and methyl.
12. The compound according to any one of claims 1 to 4 and 6 to 9, wherein R6 is selected from C 1-6 Alkyl and C 3-6 Cycloalkyl.
13. The compound according to claim 12, wherein R6 is selected from methyl, propyl and cyclopropyl.
14. The compound according to claim 5, wherein R2 is selected from methyl, ethyl, difluoromethyl, isopropyl, cyclobutane, cyclopropane, methoxy, formyl, -CH2C(=O)NH2, -S(O)2CH3, -S(O)2(CH2)2CH3, 、-C(=O)CH2N(CH3)2、 .
15. The compound according to claim 5, wherein Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , .
16. The compound according to claim 1, wherein R1 is methyl.
17. The compound according to claim 1, wherein R3 is selected from bromine, fluorine, chlorine, cyano, trifluoromethyl, methyl.
18. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Including compounds represented by formula (II) or pharmaceutically acceptable salts thereof: wherein n, m, A, L, R1, R2 and R3 are defined the same as those of the compound of formula (I).
19. The compound according to claim 18, wherein The compound of formula (II) has a structure shown by formula (IIa), (IIb) or (IIf): 、 、 ; Wherein, n, m, R1, R2 and R3 are defined the same as those of the compound of formula (I).
20. A compound represented by formula (IIc) or a pharmaceutically acceptable salt thereof, ; in, X4, X5, X6 are selected from N, NH or CH, m is selected from 0, 1, 2 or 3; n is selected from 0, 1, 2 or 3; m R2 are the same or different from each other, wherein R2 is selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-6 Acyl, -S(O)2R6, 5-7 membered heterocycloalkyl, the C 1-6 Acyl, 5-7 membered heterocycloalkyl, optionally substituted with one or more C 1-3 Alkyl, -NR4R5 substituted, the C 1-6 The alkyl group is optionally substituted with one or more halogen, -C(=O)NR4R5; n R3 are the same or different from each other, wherein R3 is selected from methyl, trifluoromethyl, cyclopropyl, halogen, cyano, ; R1 is selected from fluorine, methyl, isopropenyl or cyclopropane; R4, R5, R6 are each independently selected from hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl.
21. The following compounds or pharmaceutically acceptable salts thereof: 。 22. A method for preparing compound A1, wherein the method is selected from the following synthetic routes: Synthetic route 1: Step 1: Suzuki coupling reaction of compound 1A and compound 1A-1 to obtain compound 1B; Step 2: Compound 1B is extracted and purified to obtain compound 1C; Step 3: Compound 1C and compound 1C-1 undergo condensation reaction to obtain compound A1; Wherein, m, n, ring A, ring B, R1, R2, and R3 are respectively as defined in claim 1; Synthesis route 2: Step 1: Compound 2A is reacted with compound 1C-1 to obtain compound 2B; Step 2: Suzuki coupling reaction of compound 2B and compound 1A-1 to obtain compound A1; Wherein, m, n, ring A, ring B, R1, R2, and R3 are respectively as defined in claim 1; Synthetic route 3: Step 1: Compound 3A is reacted with compound 1C-1 to obtain compound 3B; Step 2: Compound 3B is reacted with R1-B(OH)2Suzuki coupling reaction to obtain compound 2B; Step 3: Suzuki coupling reaction of compound 2B and compound 1A-1 to obtain compound A1; Wherein, m, n, ring A, ring B, R1, R2, and R3 are respectively defined as in claim 1.
23. A pharmaceutical composition, characterized in that The composition comprises the compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
24. Use of the compound of any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 23, in the preparation of a medicament for treating an AhR-mediated disorder in a patient.
25. Use of the compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 23 in the preparation of an AHR agonist.
